Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months

Fig. 1

Proportion of patients with and without relapses (A) and severity of relapses during 48 months of treatment with fingolimod (B). Data presented as percentage of patients (Wald 95% CI) CI, confidence interval; MS, multiple sclerosis; N, total number of patients in the set; N’, total number of patients with relapses; n, number of patients with the outcome

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us